BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Covington
Cipla
Farmers Insurance
Boehringer Ingelheim
Merck
Deloitte
Chubb
Daiichi Sankyo
AstraZeneca

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,548,078

« Back to Dashboard

Which drugs does patent 6,548,078 protect, and when does it expire?

Patent 6,548,078 protects ILUVIEN and RETISERT and is included in two NDAs.

This patent has ten patent family members in eight countries.
Summary for Patent: 6,548,078
Title: Method for treating and/or preventing retinal diseases with sustained release corticosteroids
Abstract:The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
Inventor(s): Guo; Hong (Belmont, MA), Ashton; Paul (Boston, MA)
Assignee: Control Delivery Systems (Watertown, MA)
Application Number:09/735,636
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 6,548,078

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Alimera Sciences Inc ILUVIEN fluocinolone acetonide IMPLANT;INTRAVITREAL 201923-001 Sep 26, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF DIABETIC MACULAR EDEMA ➤ Subscribe
Bausch And Lomb RETISERT fluocinolone acetonide IMPLANT;INTRAVITREAL 021737-001 Apr 8, 2005 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,548,078

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,217,895 Method for treating and/or preventing retinal diseases with sustained release corticosteroids ➤ Subscribe
8,252,307 Method for treating and/or preventing retinal diseases with sustained release corticosteroids ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,548,078

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005200243 ➤ Subscribe
Australia 4174800 ➤ Subscribe
Australia 777727 ➤ Subscribe
Brazil 0010869 ➤ Subscribe
Canada 2367092 ➤ Subscribe
European Patent Office 1162978 ➤ Subscribe
Japan 2002539263 ➤ Subscribe
South Korea 20010112357 ➤ Subscribe
Mexico PA01009544 ➤ Subscribe
World Intellectual Property Organization (WIPO) 0056340 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Fish and Richardson
US Army
McKinsey
Cerilliant
UBS
Farmers Insurance
Citi
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot